278 related articles for article (PubMed ID: 25681663)
1. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).
Wu DB; Chaiyakunapruk N; Chong HY; Beutels P
Vaccine; 2015 Mar; 33(14):1633-58. PubMed ID: 25681663
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
[TBL] [Abstract][Full Text] [Related]
4. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
Mezones-Holguín E; Bolaños-Díaz R; Fiestas V; Sanabria C; Gutiérrez-Aguado A; Fiestas F; Suárez VJ; Rodriguez-Morales AJ; Hernández AV
J Infect Dev Ctries; 2014 Dec; 8(12):1552-62. PubMed ID: 25500653
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
10. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
[TBL] [Abstract][Full Text] [Related]
15. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.
Treskova M; Scholz SM; Kuhlmann A
Pharmacoeconomics; 2019 Sep; 37(9):1093-1127. PubMed ID: 31025189
[TBL] [Abstract][Full Text] [Related]
19. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
Rubin JL; McGarry LJ; Strutton DR; Klugman KP; Pelton SI; Gilmore KE; Weinstein MC
Vaccine; 2010 Nov; 28(48):7634-43. PubMed ID: 20883739
[TBL] [Abstract][Full Text] [Related]
20. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
